Cantor Fitzgerald Reiterates Overweight Rating on Structure Therapeutics (GPCR)

Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating and $65.00 price target on Structure Therapeutics (NASDAQ: GPCR).

The analyst commented, "GPCR has a big catalyst by year-end 2025 - P2B obesity readouts (ACCESS-1 and ACCESS-2 trials) for oral GLP-1 aleniglipron. GPCR valuation at $1.3B market cap (EV of ~$500M) remains very attractive into this catalyst. Recent orfor obesity data has created a better set-up for GPCR with risk/reward meaningfully skewed to the upside as the bar for aleniglipron is no longer high. 2026 will have several readouts that can really differentiate GPCR’s pipeline – oral amylin, longer duration readout for higher doses of aleniglipron."

For an analyst ratings summary and ratings history on Structure Therapeutics click here. For more ratings news on Structure Therapeutics click here.

Shares of Structure Therapeutics closed at $22.08 yesterday.

You May Also Be Interested In

• Goldman Sachs Starts Excelerate Energy Inc (EE) at Buy
• JPMorgan Reiterates Overweight Rating on SpaceX (SPCX)
• Morgan Stanley Upgrades Rocket Cos Inc. (RKT) to Overweight